Senate confirms Trump health secretary

The Department of Health and Human Services (HHS) has a new boss, Alex Azar, after nearly four months without a permanent leader.

The Senate confirmed Azar, a former pharmaceutical executive, on Wednesday by a 55-43 vote with six Democrats and Independent Sen. Angus KingAngus Stanley KingRestoring our national parks would be a bipartisan win for Congress Restore our parks Renaming Senate office building after McCain sparks GOP backlash MORE (Maine) joining all but one Republican to support the nominee.

Sen. Rand PaulRandal (Rand) Howard PaulConservatives left frustrated as Congress passes big spending bills Senate approves 4B spending bill Some employees' personal data revealed in State Department email breach: report MORE (R-Ky.) was the lone Republican to vote against his confirmation, after having previously expressed concern over Azar's reticence to let drugs be imported from overseas.

Azar replaces Tom PriceThomas (Tom) Edmunds PriceWhite House officials discussing potential replacements for FEMA chief: report Overnight Health Care: CBO finds bill delaying parts of ObamaCare costs B | Drug CEO defends 400 percent price hike | HHS declares health emergency ahead of hurricane HHS should look into Azar's close ties to the drug industry MORE, who resigned in September after Politico detailed repeated trips he took on private and military jets, costing taxpayers more than $1 million.

ADVERTISEMENT

Democrats have attacked Azar over drug prices — saying the cost of several drugs more than doubled during his time at Eli Lilly — and expressed concern that he would continue what they view as the Trump administration’s attempts to sabotage ObamaCare.

Meanwhile, Republicans cast Azar’s nearly 10 year tenure at Eli Lilly, where he served as president of Lilly USA from 2012 to 2017 years, as an asset because he already knows the ins and outs of such a complex industry.

Azar will take the helm of the massive department at a critical juncture for ObamaCare. It’s unlikely congressional Republicans will return to the difficult task of repealing and replacing President Obama’s signature health-care law, leaving the White House to seek changes on its own through administrative action.

Azar knows the regulatory process well. Under former President George W. Bush, he served HHS as general counsel from 2001 to 2005. He then became deputy secretary for two years under Secretary Mike Leavitt, who asked Azar to oversee the department’s regulatory process.

“He understands the process and he knows the levers and how you make it work and where the potential roadblocks are,” Leavitt told The Hill last year. “I think he would be of particular value given the fact that ... so far a repeal bill has not occurred and they’re going to need to make their imprint on existing laws through replacing the ideology underpinning it.”

Prescription drugs prices are also likely to be discussed under Azar's tenure. Lawmakers have criticized the high costs of prescription drugs, and President TrumpDonald John TrumpHannity urges Trump not to fire 'anybody' after Rosenstein report Ben Carson appears to tie allegation against Kavanaugh to socialist plot Five takeaways from Cruz, O'Rourke's fiery first debate MORE has said drug companies were “getting away with murder.” In nomination hearings, Azar said “drug prices are too high.”

But in those hearings, Democrats expressed concerns over Azar’s record as a pharmaceutical executive, and that was, in part, a reason why some senators voted against his confirmation.

“Here’s my view: Mr. Azar’s nomination is a perfect encapsulation of the president’s broken promises on prescription drugs and health care overall,” Sen. Ron WydenRonald (Ron) Lee WydenHillicon Valley: NYT says Rosenstein wanted to wear wire on Trump | Twitter bug shared some private messages | Vendor put remote-access software on voting machines | Paypal cuts ties with Infowars | Google warned senators about foreign hacks Overnight Health Care: Opioids package nears finish line | Measure to help drug companies draws ire | Maryland ObamaCare rates to drop Google says senators' Gmail accounts targeted by foreign hackers MORE (D-Ore.), the top Democrat on the Senate Finance Committee, said in a press release ahead of a procedural vote on Azar’s confirmation.

The panel’s chairman, Sen. Orrin HatchOrrin Grant HatchJudiciary Dems say GOP treating Kavanaugh accuser worse than Anita Hill Dem vows to probe 'why the FBI stood down' on Kavanaugh Senate Democrats increase pressure for FBI investigation of Kavanaugh MORE (R-Utah) has countered that Azar has the right experience to helm HHS, which oversees everything from Medicare and Medicaid to drug approvals and disease control.

“Mr. Azar spent several years as a senior official at HHS, holding key positions overseeing Medicare Part D and Medicare Advantage. He also led HHS’s responses to the anthrax attacks shortly after 9/11, the SARS and monkeypox crises, Hurricane Katrina, and many others,” Hatch said in a press release ahead of the confirmation vote.

“Clearly, Mr. Azar has seen both the good and bad at HHS and knows how to manage them. I don’t think there is anyone here, even on the other side of the aisle, who would contest that.”

The six Democrats who voted for Azar are Sens. Tom CarperThomas (Tom) Richard CarperTrump Jr. to Dem Senator: 'You admitted to hitting your wife so hard it gave her a black eye!' Melania Trump's spokeswoman gets Hatch Act warning for #MAGA tweet EPA to abandon restrictions against chemical linked to climate change MORE (Del.), Christopher CoonsChristopher (Chris) Andrew CoonsJudiciary Democrat calls for additional witnesses to testify on Kavanaugh Kavanaugh allegations could be monster storm brewing for midterm elections      Sunday shows preview: White House officials on offensive in wake of anonymous NY Times op-ed MORE (Del.), Joe DonnellyJoseph (Joe) Simon DonnellyThe Memo: Tide turns on Kavanaugh McCaskill to oppose Kavanaugh nomination The Memo: Kavanaugh firestorm consumes political world MORE (Ind.), Heidi HeitkampMary (Heidi) Kathryn HeitkampGOP Senate candidate: Allegations against Kavanaugh 'absurd' The Memo: Tide turns on Kavanaugh McCaskill to oppose Kavanaugh nomination MORE (N.D.), Doug Jones (Ala.) and Joe ManchinJoseph (Joe) ManchinCook Political Report moves Texas Senate race to ‘toss-up’ The Memo: Tide turns on Kavanaugh McCaskill to oppose Kavanaugh nomination MORE (W.Va.).